×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
合肥物质科学研究院 [21]
内容类型
期刊论文 [21]
发表日期
2023 [1]
2022 [9]
2021 [7]
2020 [2]
2018 [1]
2016 [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共21条,第1-10条
帮助
限定条件
专题:合肥物质科学研究院
第一署名单位
第一作者单位
通讯作者单位
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
期刊论文
BLOOD ADVANCES, 2023, 卷号: 7
作者:
Bachy, Emmanuel
;
Savage, Kerry J.
;
Huang, Huiqiang
;
Kwong, Yok-Lam
;
Gritti, Giuseppe
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2023/11/10
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
期刊论文
THORACIC CANCER, 2022
作者:
Wang, Wenxian
;
Wang, Qian
;
Xu, Chunwei
;
Li, Ziming
;
Song, Zhengbo
收藏
  |  
浏览/下载:32/0
  |  
提交时间:2022/12/23
checkpoint inhibitor pneumonitis
Chinese experts consensus
immune checkpoint inhibitor-related adverse effects
The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
期刊论文
CANCERS, 2022, 卷号: 14
作者:
Xie, Mingying
;
Li, Na
;
Xu, Xiaoling
;
Xu, Yanjun
;
Li, Hui
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2022/12/22
liver metastasis
non-small cell lung cancer
PD-L1
PD-1
PD-L1 inhibitor
CD8+T cell
Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17
作者:
Wu, Y. -L.
;
Zhou, Q.
;
Chen, M.
;
Pan, Y.
;
Jian, O.
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2022/12/23
CCRT
sCRT
PD-L1 inhibitor
Ratiometric co-delivery of hydroxychloroquine and calculated low-dose paclitaxel efficiently suppresses tumor growth in hepatocellular carcinoma mouse models in vivo
期刊论文
NANO TODAY, 2022, 卷号: 44
作者:
Wang, Wenbin
;
Sun, Hui
;
Gong, Yan
;
Liu, Xiangsheng
;
Liu, Xiao
收藏
  |  
浏览/下载:120/0
  |  
提交时间:2022/12/23
Ratiometric co-delivery
Autophagy
Hepatocellular carcinoma
Chemo-immunotherapy
Hydroxychloroquine
Paclitaxel
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:
Bachy, Emmanuel
;
Savage, Kerry J.
;
Huang, Huiqiang
;
Kwong, Yok-Lam
;
Gritti, Giuseppe
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2022/12/23
Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study
期刊论文
GENES CHROMOSOMES & CANCER, 2022
作者:
Wang, Wenxian
;
Gu, Xiaodong
;
Si, Jinfei
;
Pu, Xingxiang
;
Wang, Liping
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2022/05/16
BRAF mutation
immune checkpoint inhibitors
non-small cell lung cancer
PD-L1
targeted therapy
BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer
期刊论文
ANTIOXIDANTS, 2022, 卷号: 11
作者:
Lv, Yang
;
Lv, Xiaotong
;
Zhang, Jiahui
;
Cao, Guozhen
;
Xu, Changzhi
收藏
  |  
浏览/下载:30/0
  |  
提交时间:2022/05/16
small cell lung cancer
BRD4
KEAP1
Nrf2
pentose phosphate pathway
Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review
期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:
Lin, Yuxin
;
Zhu, Wei
;
Wu, Bingchen
;
Lan, Huiyin
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2022/05/16
Sarcoid-like reaction
immune checkpoint inhibitor
Toripalimab
PD-1
case report
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
期刊论文
BMC CANCER, 2022, 卷号: 22
作者:
Chen, Xi
;
Kong, Haiying
;
Luo, Linxiang
;
Han, Shuiyun
;
Lei, Tao
收藏
  |  
浏览/下载:43/0
  |  
提交时间:2022/02/14
Hodgkin lymphoma
PD-1 inhibitor
PD-L1 inhibitor
PD-L2
Molecular phenotype
Tumor microenvironment
©版权所有 ©2017 CSpace - Powered by
CSpace